Novel product shown to reduce pancreatic cancer tumor size secures issued patent
Anviron is the exclusive licensee of the technology for the patent issued to the UT Research Foundation and the California Institute of Technology.
A start-up that was founded in 2020 and is leveraging technology created at the University of Tennessee Health Science Center (UTHSC) is now one step closer to commercializing a novel product candidate shown to reduce pancreatic cancer tumor size and suppress metastases.
In March 2023, the U.S. Patent and Trademark Office issued a patent to the UT Research Foundation and California Institute of Technology for ANV221, an anti-cancer compound exclusively licensed to biotechnology start-up Anviron. The start-up is located in Newport Beach, CA.
ANV221 is a DPAGT-1 inhibitor with orphan drug designation by the Food and Drug Administration for the treatment of pancreatic cancer. In 2020, UTRF licensed the technology to Anviron and Brad Morrison, the company’s Co-Founder. Anviron is currently competing for more than $6 million in cancer research funding and will be announcing a stock offering later this summer to prepare ANV221 for a Phase 1 clinical trial.
Michio Kurosu, a Professor in the Department of Pharmaceutical Sciences at UTHSC College of Pharmacy, invented the technology, while Evan Glazer, a Professor in the Division of Surgical Oncology at UTHSC’s College of Medicine, provided clinical advising.